Skip to main content

Advertisement

SpringerLink
Log in

Management of Potential Long-Term Toxicities in Breast Cancer Patients

  • Systemic Therapies (M Liu and T Haddad, Section Editors)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Breast cancer is the most common non-cutaneous malignancy among women, and there are over 3 million breast cancer survivors living in the USA today. Excellent cure rates with modern therapies are associated with substantial toxicities for many women; it is important that healthcare providers attend to the resulting symptoms and issues to optimize quality of life in this population. In this article, we review management options for potential long-term toxicities in breast cancer survivors, with a particular focus on bone health, fertility preservation, premature menopause, cardiac dysfunction, and cognitive impairment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  2. Howlader N, Noone AM, Krapcho M, et al., editors. SEER cancer statistics review, 1975-2012. Bethesda: National Cancer Institute; 2015. http://seer.cancer.gov/csr.1975-2012/.

    Google Scholar 

  3. Almstedt K, Schmidt M. Targeted therapies overcoming endocrine resistance in hormone receptor-positive breast cancer. Breast Care (Basel). 2015;10(3):168–72.

    Article  Google Scholar 

  4. Clines GA, Choksi P, Van Poznak C. Adjuvant endocrine therapy and bone health in breast cancer. Curr Osteoporos Rep. 2015;13(5):263–73.

    Article  PubMed  Google Scholar 

  5. Hagiwara M, Delea TE, Chung K. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases. J Med Econ. 2014;17(3):223–30.

    Article  PubMed  Google Scholar 

  6. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14(1):78–84.

    CAS  PubMed  Google Scholar 

  7. Paterson AH, Shea-Budgell MA. Bone health in patients with breast cancer: recommendations from an evidence-based Canadian guideline. J Clin Med. 2013;2(4):283–301.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353–61.

    Article  CAS  PubMed  Google Scholar 

  9. Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012;118(5):1192–201.

    Article  CAS  PubMed  Google Scholar 

  10. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010;21(11):2188–94.

    Article  CAS  PubMed  Google Scholar 

  11. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631–41.

    Article  CAS  PubMed  Google Scholar 

  12. Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15(9):997–1006.

    Article  CAS  PubMed  Google Scholar 

  13. Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433–43.

    Article  CAS  PubMed  Google Scholar 

  14. Sulmasy D, Moy B. Debating the oncologist’s role in defining the value of cancer care: our duty is to our patients. J Clin Oncol. 2014;32(36):4039–41.

    Article  PubMed  Google Scholar 

  15. Rizzoli R, Body JJ, DeCensi A, Reginster JY, Piscitelli P, Brandi ML. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int. 2012;23(11):2567–76.

    Article  CAS  PubMed  Google Scholar 

  16. Hadji P, Coleman RE, Wilson C, Powles TJ, Clezardin P, Aapro M, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel. Ann Oncol. 2016;27(3):379–90.

    Article  CAS  PubMed  Google Scholar 

  17. Gnant M. Role of bisphosphonates in postmenopausal women with breast cancer. Cancer Treat Rev. 2014;40(3):476–84.

    Article  CAS  PubMed  Google Scholar 

  18. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23–57.

    Article  CAS  PubMed  Google Scholar 

  19. Hadji P, Hartenfels M, Kyvernitakis J, Hars O, Baumann KH, Kalder M. Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES). Breast Cancer Res Treat. 2012;133(3):1089–96.

    Article  CAS  PubMed  Google Scholar 

  20. Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J. 2010;16(1):76–82.

    Article  PubMed  Google Scholar 

  21. Cooke A, Mills TA, Lavender T. ‘Informed and uninformed decision making’—women’s reasoning, experiences and perceptions with regard to advanced maternal age and delayed childbearing: a meta-synthesis. Int J Nurs Stud. 2010;47(10):1317–29.

    Article  PubMed  Google Scholar 

  22. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10.

    Article  PubMed  Google Scholar 

  23. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006;24(36):5769–79.

    Article  CAS  PubMed  Google Scholar 

  24. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986;1:105–9.

    Google Scholar 

  25. Johnston SR, Yeo B. The optimal duration of adjuvant endocrine therapy for early stage breast cancer—with what drugs and for how long? Curr Oncol Rep. 2014;16(1):358.

    Article  PubMed  CAS  Google Scholar 

  26. Pagani O, Azim Jr H. Pregnancy after breast cancer: myths and facts. Breast Care (Basel). 2012;7(3):210–4.

    Article  Google Scholar 

  27. Christinat A, Pagani O. Fertility after breast cancer. Maturitas. 2012;73(3):191–6.

    Article  PubMed  Google Scholar 

  28. Waks AG, Partridge AH. Fertility preservation in patients with breast cancer: necessity, methods, and safety. J Natl Compr Canc Netw. 2016;14(3):355–63. Review article summarizing best practices for fertility preservation in breast cancer patients.

    PubMed  Google Scholar 

  29. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim Jr HA, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14:1.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Rudick B, Opper N, Paulson R, Bendikson K, Chung K. The status of oocyte cryopreservation in the United States. Fertil Steril. 2010;94(7):2642–6.

    Article  PubMed  Google Scholar 

  31. Rodriguez-Wallberg KA, Oktay K. Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer. Oncologist. 2012;17(11):1409–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630–5.

    Article  CAS  PubMed  Google Scholar 

  33. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347–53.

    Article  CAS  PubMed  Google Scholar 

  34. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18(1):90–5.

    Article  CAS  PubMed  Google Scholar 

  35. Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol. 2015;33(22):2424–9.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269–76.

    PubMed  Google Scholar 

  37. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923–32. Randomized controlled trial showing some protection against ovarian dysfunction when goserelin was administered during chemotherapy for early-stage breast cancer.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Balthazar U, Deal AM, Fritz MA, Kondapalli LA, Kim JY, Mersereau JE. The current fertility preservation consultation model: are we adequately informing cancer patients of their options? Hum Reprod. 2012;27(8):2413–9.

    Article  PubMed  Google Scholar 

  39. Christianson MS, Yates MM, Woo I, Khafagy A, Garcia JE, Kolp LA. Women of reproductive age receiving gonadotoxic treatment: needs assessment and predictive patterns for fertility preservation. Presented at the American Society of Reproductive Medicine Annual Meeting. 2012.

    Google Scholar 

  40. Kim J, Oktay K, Gracia C, Lee S, Morse C, Mersereau JE. Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancer. Fertil Steril. 2012;97(3):671–6.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Stensheim H, Cvancarova M, Moller B, Fossa SD. Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer. 2011;129(5):1225–36.

    Article  CAS  PubMed  Google Scholar 

  42. Lee S, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol. 2010;28(31):4683–6.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Quinn GP, Vadaparampil ST, Lee JH, Jacobsen PB, Bepler G, Lancaster J, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009;27(35):5952–7.

    Article  PubMed  Google Scholar 

  44. Clayman ML, Harper MM, Quinn GP, Reinecke J, Shah S. Oncofertility resources at NCI-designated comprehensive cancer centers. J Natl Compr Canc Netw. 2013;11(12):1504–9.

    PubMed  PubMed Central  Google Scholar 

  45. Lawrenz B, Jauckus J, Kupka MS, Strowitzki T, von Wolff M. Fertility preservation in >1,000 patients: patient’s characteristics, spectrum, efficacy and risks of applied preservation techniques. Arch Gynecol Obstet. 2011;283(3):651–6.

    Article  PubMed  Google Scholar 

  46. Rodriguez S, Campo-Engelstein L, Emanuel L. Fertile future? Potential social implications of oncofertility. J Clin Oncol. 2013;31(6):665–7.

    Article  PubMed  Google Scholar 

  47. Campo-Engelstein L. Consistency in insurance coverage for iatrogenic conditions resulting from cancer treatment including fertility preservation. J Clin Oncol. 2010;28(8):1284–6.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Levine JM, Kelvin JF, Quinn GP, Gracia CR. Infertility in reproductive-age female cancer survivors. Cancer. 2015;121(10):1532–9.

    Article  PubMed  Google Scholar 

  49. Azim Jr HA, Santoro L, Pavlidis N, Gelber S, Kroman N, Azim H, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 2011;47(1):74–83.

    Article  PubMed  Google Scholar 

  50. Madanat LM, Malila N, Dyba T, Hakulinen T, Sankila R, Boice Jr JD, et al. Probability of parenthood after early onset cancer: a population-based study. Int J Cancer. 2008;123(12):2891–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Goldfarb S, Mulhall J, Nelson C, Kelvin J, Dickler M, Carter J. Sexual and reproductive health in cancer survivors. Semin Oncol. 2013;40:726–44.

    Article  PubMed  Google Scholar 

  52. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10:1790–9.

    Article  PubMed  Google Scholar 

  53. Simon JA, Nappi RE, Kingsberg SA, Maamari R, Brown V. Clarifying Vaginal Atrophy’s Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause. 2014;21(2):137–42.

    Article  PubMed  Google Scholar 

  54. Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100(7):475–82.

    Article  CAS  PubMed  Google Scholar 

  55. Caan BJ, Emond JA, Su HI, Patterson RE, Flatt SW, Gold EB, et al. Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors. J Clin Oncol. 2012;30(13):1492–7.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. 2015 position statement of The North American Menopause Society. Menopause. 2015;22(11):1155–72. Review of non-hormonal management strategies for menopausal symptoms in the general population.

    Article  Google Scholar 

  57. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol. 1992;167(2):436–9.

    Article  CAS  PubMed  Google Scholar 

  58. Irvin JH, Domar AD, Clark C, Zuttermeister PC, Friedman R. The effects of relaxation response training on menopausal symptoms. J Psychosom Obstet Gynaecol. 1996;17(4):202–7.

    Article  CAS  PubMed  Google Scholar 

  59. Wijma K, Melin A, Nedstrand E, Hammar M. Treatment of menopausal symptoms with applied relaxation: a pilot study. J Behav Ther Exp Psychiatry. 1997;28(4):251–61.

    Article  CAS  PubMed  Google Scholar 

  60. Carpenter JS, Burns DS, Wu J, Otte JL, Schneider B, Ryker K, et al. Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial. J Gen Intern Med. 2013;28(2):193–200.

    Article  PubMed  Google Scholar 

  61. Sood R, Sood A, Wolf SL, Linquist BM, Liu H, Sloan JA, et al. Paced breathing compared with usual breathing for hot flashes. Menopause. 2013;20(2):179–84.

    PubMed  Google Scholar 

  62. Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause. 2012;19(7):749–59.

    Article  PubMed  Google Scholar 

  63. Mann E, Smith MJ, Hellier J, Balabanovic JA, Hamed H, Grunfeld EA, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13(3):309–18.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Elkins G, Marcus J, Palamara L, Stearns V. Can hypnosis reduce hot flashes in breast cancer survivors? A literature review. Am J Clin Hypn. 2004;47(1):29–42.

    Article  PubMed  Google Scholar 

  65. Elkins G, Marcus J, Stearns V, Hasan RM. Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors. Psychooncology. 2007;16(5):487–92.

    Article  PubMed  Google Scholar 

  66. Elkins G, Marcus J, Stearns V, Perfect M, Rajab MH, Ruud C, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol. 2008;26(31):5022–6.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Barton D, Free-Schroeder K, Linquist B, et al. Pilot study of a biobehavioral treatment for hot flashes. Ann Behav Med. 2013;45:Abstract A–130.

    Google Scholar 

  68. Mao JJ, Bowman MA, Xie SX, Bruner D, DeMichele A, Farrar JT. Electroacupuncture versus gabapentin for hot flashes among breast cancer survivors: a randomized placebo-controlled trial. J Clin Oncol. 2015;33(31):3615–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Fugh-Berman A, Kronenberg F. Complementary and alternative medicine (CAM) in reproductive-age women: a review of randomized controlled trials. Reprod Toxicol. 2003;17(2):137–52.

    Article  CAS  PubMed  Google Scholar 

  70. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013;12:Cd001395.

    Google Scholar 

  71. Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol. 2000;18(5):1068–74.

    CAS  PubMed  Google Scholar 

  72. Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton DL, Sloan JA, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol. 2006;24(18):2836–41.

    Article  PubMed  Google Scholar 

  73. Park H, Qin R, Smith TJ, Atherton PJ, Barton DL, Sturtz K, et al. North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause. 2015;22(6):627–32.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Pruthi S, Qin R, Terstreip SA, Liu H, Loprinzi CL, Shah TR, et al. A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause. 2012;19(1):48–53.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998;16(2):495–500.

    CAS  PubMed  Google Scholar 

  76. Goldberg RM, Loprinzi CL, O’Fallon JR, Veeder MH, Miser AW, Mailliard JA, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994;12(1):155–8.

    CAS  PubMed  Google Scholar 

  77. Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000;132(10):788–93.

    Article  CAS  PubMed  Google Scholar 

  78. Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J. 2006;12(2):114–22.

    Article  PubMed  Google Scholar 

  79. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20(6):1578–83.

    Article  CAS  PubMed  Google Scholar 

  80. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003;289(21):2827–34.

    Article  CAS  PubMed  Google Scholar 

  81. Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005;23(28):6919–30.

    Article  CAS  PubMed  Google Scholar 

  82. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol. 2009;200(2):172.e1–10.

    Article  CAS  Google Scholar 

  83. Barton DL, LaVasseur BI, Sloan JA, Stawis AN, Flynn KA, Dyar M, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol. 2010;28(20):3278–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Carpenter JS, Guthrie KA, Larson JC, Freeman EW, Joffe H, Reed SD, et al. Effect of escitalopram on hot flash interference: a randomized, controlled trial. Fertil Steril. 2012;97(6):1399–404.e1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Freedman RR, Kruger ML, Tancer ME. Escitalopram treatment of menopausal hot flashes. Menopause. 2011;18(8):893–6.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011;305(3):267–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Soares CN. Escitalopram reduced hot flashes in non-depressed perimenopausal and postmenopausal women. Evid Based Med. 2011;16(5):159–60.

    Article  PubMed  Google Scholar 

  88. Simon JA, Portman DJ, Kaunitz AM, Mekonnen H, Kazempour K, Bhaskar S, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013;20(10):1027–35.

    Article  PubMed  Google Scholar 

  89. Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause. 2008;15(2):310–8.

    Article  PubMed  Google Scholar 

  90. Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005;366(9488):818–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Reddy SY, Warner H, Guttuso Jr T, Messing S, DiGrazio W, Thornburg L, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol. 2006;108(1):41–8.

    Article  CAS  PubMed  Google Scholar 

  92. Loprinzi CL, Qin R, Balcueva EP, Flynn KA, Rowland Jr KM, Graham DL, et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol. 2010;28(4):641–7.

    Article  CAS  PubMed  Google Scholar 

  93. Bordeleau L, Pritchard KI, Loprinzi CL, Ennis M, Jugovic O, Warr D, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010;28(35):5147–52.

    Article  CAS  PubMed  Google Scholar 

  94. Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–46.

    Article  PubMed  CAS  Google Scholar 

  95. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–18.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  96. Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med. 2013;10(6):1575–84.

    Article  CAS  PubMed  Google Scholar 

  97. Salvatore S, Nappi RE, Parma M, Chionna R, Lagona F, Zerbinati N, et al. Sexual function after fractional microablative CO(2) laser in women with vulvovaginal atrophy. Climacteric. 2015;18(2):219–25.

    Article  CAS  PubMed  Google Scholar 

  98. Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17(4):363–9.

    Article  CAS  PubMed  Google Scholar 

  99. Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2015;33(30):3394–400. Randomized controlled trial that found significant improvement in sexual functioning with the use of liquid lidocaine compresses before penetration.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Management of symptomatic vulvovaginal atrophy. 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902. quiz 3-4.

    Article  Google Scholar 

  101. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17(4):584–7.

    Article  CAS  PubMed  Google Scholar 

  102. Wills SRA, Venuturumilli M. The effects of vaginal estrogens (VE) on serum estradiol levels in postmenopausal breast cancer survivors receiving an aromatase inhibitor (AI) or a selective estrogen receptor modulator (SERM). Cancer Res Suppl. 2009;69:806.

    Article  Google Scholar 

  103. Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract. 2012;8(3):144–8.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist. 2011;16(4):424–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Thavendiranathan P, Abdel-Qadir H, Fischer HD, Camacho X, Amir E, Austin PC, et al. Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study. J Clin Oncol. 2016;34(19):2239–46.

    Article  PubMed  Google Scholar 

  106. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104(17):1293–305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23(34):8597–605.

    Article  PubMed  Google Scholar 

  108. Zambetti M, Moliterni A, Materazzo C, Stefanelli M, Cipriani S, Valagussa P, et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol. 2001;19(1):37–43.

    CAS  PubMed  Google Scholar 

  109. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302–13.

    Article  CAS  PubMed  Google Scholar 

  110. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808–15.

    Article  CAS  PubMed  Google Scholar 

  111. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13(5):699–709.

    Article  CAS  PubMed  Google Scholar 

  112. Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S, et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005;24(12):2196–201.

    Article  PubMed  Google Scholar 

  113. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258–62.

    Article  CAS  PubMed  Google Scholar 

  114. Hermelink K. Chemotherapy and cognitive function in breast cancer patients: the so-called chemo brain. J Natl Cancer Inst Monogr. 2015;2015(51):67–9.

    Article  PubMed  Google Scholar 

  115. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3(4):223–32.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Schmidt JE, Beckjord E, Bovbjerg DH, Low CA, Posluszny DM, Lowery AE, et al. Prevalence of perceived cognitive dysfunction in survivors of a wide range of cancers: results from the 2010 LIVESTRONG survey. J Cancer Surviv. 2016;10(2):302–11.

    Article  PubMed  Google Scholar 

  117. Kesler SR, Blayney DW. Neurotoxic effects of anthracycline- vs nonanthracycline-based chemotherapy on cognition in breast cancer survivors. JAMA Oncol. 2016;2(2):185–92.

    Article  PubMed  Google Scholar 

  118. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59(1):60–70.

    Article  PubMed  Google Scholar 

  119. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. ‘Chemobrain’ in breast carcinoma?: a prologue. Cancer. 2004;101(3):466–75.

    Article  PubMed  Google Scholar 

  120. Lycke M, Pottel L, Pottel H, Ketelaars L, Stellamans K, Van Eygen K, et al. Predictors of baseline cancer-related cognitive impairment in cancer patients scheduled for a curative treatment. Psycho-oncology. 2016. doi:10.1002/pon.4200.

  121. Bender CM, Merriman JD, Gentry AL, Ahrendt GM, Berga SL, Brufsky AM, et al. Patterns of change in cognitive function with anastrozole therapy. Cancer. 2015;121(15):2627–36.

    Article  CAS  PubMed  Google Scholar 

  122. Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30(30):3675–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116(14):3348–56.

    Article  PubMed  Google Scholar 

  124. Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30(29):3578–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012;38(7):926–34.

    Article  PubMed  Google Scholar 

  126. McDonald BC, Conroy SK, Smith DJ, West JD, Saykin AJ. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(Suppl):S117–25.

    Article  PubMed  Google Scholar 

  127. Kesler SR, Kent JS, O’Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol. 2011;68(11):1447–53.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Morean DF, O’Dwyer L, Cherney LR. Therapies for cognitive deficits associated with chemotherapy for breast cancer: a systematic review of objective outcomes. Arch Phys Med Rehabil. 2015;96(10):1880–97.

    Article  PubMed  Google Scholar 

  129. Henneghan A. Modifiable factors and cognitive dysfunction in breast cancer survivors: a mixed-method systematic review. Support Care Cancer. 2016;24(1):481–97.

    Article  PubMed  Google Scholar 

  130. Johns SA, Von Ah D, Brown LF, Beck-Coon K, Talib TL, Alyea JM, et al. Randomized controlled pilot trial of mindfulness-based stress reduction for breast and colorectal cancer survivors: effects on cancer-related cognitive impairment. J Cancer Surviv. 2016;10(3):437–48.

    Article  PubMed  Google Scholar 

  131. Ferguson RJ, Sigmon ST, Pritchard AJ, LaBrie SL, Goetze RE, Fink CM, et al. A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. Cancer. 2016;122(11):1782–91. Reports results from a randomized controlled trial showing benefit from cognitive behavioral therapy in treating cognitive dysfunction in breast cancer survivors.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA

    C. C. O’Sullivan & Kathryn J. Ruddy

Authors
  1. C. C. O’Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathryn J. Ruddy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathryn J. Ruddy.

Ethics declarations

Conflict of Interest

Ciara C. O’Sullivan and Kathryn J. Ruddy declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Systemic Therapies

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

O’Sullivan, C.C., Ruddy, K.J. Management of Potential Long-Term Toxicities in Breast Cancer Patients. Curr Breast Cancer Rep 8, 183–192 (2016). https://doi.org/10.1007/s12609-016-0229-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-016-0229-0

Keywords

Search

Navigation